Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Approves Hibsago

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

Back to Pharmaceutical Executive · Report a problem